Literature DB >> 8922581

Evaluation of four commercial enzyme immunoassays for detection of immunoglobulin M antibodies to human parvovirus B19.

T Sloots1, P L Devine.   

Abstract

Four commercial enzyme immunoassays (EIAs) for the detection of parvovirus B19-specific immunoglobulin M (IgM) antibodies [Biotrin Parvovirus B19 IgM (Biotrin International, Ireland); Parvoscan B19 IgM (Euro-Diagnostica, Sweden); Parvovirus IgM (Immunobiological Laboratories [IBL], Germany); and human parvovirus B19 IgM (Hillcrest Biologicals, USA)] were compared to indirect immunofluorescence assay (IFA) and polymerase chain reaction (PCR). Using IFA as the reference test, high sensitivities (> or = 97%) were observed with all four EIAs, though the specificities of the Biotrin and IBL EIAs (99% and 96% respectively) were significantly higher than those of the Hillcrest and Euro-Diagnostica EIAs (81% and 79% respectively).

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8922581     DOI： 10.1007/bf01691968

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  14 in total

Review 1.  Parvovirus B19 and human disease.

Authors:  T J Török
Journal:  Adv Intern Med       Date:  1992

2.  A new peptide for human parvovirus B19 antibody detection.

Authors:  E Fridell; J Trojnar; B Wahren
Journal:  Scand J Infect Dis       Date:  1989

3.  Cross-reactions in rubella and parvovirus specific IgM tests.

Authors:  J B Kurtz; M J Anderson
Journal:  Lancet       Date:  1985-12-14       Impact factor: 79.321

4.  Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity.

Authors:  J J Gray; B J Cohen; U Desselberger
Journal:  J Virol Methods       Date:  1993-09       Impact factor: 2.014

5.  Rapid detection of human parvovirus B19 DNA by dot-hybridization and the polymerase chain reaction.

Authors:  M M Salimans; S Holsappel; F M van de Rijke; N M Jiwa; A K Raap; H T Weiland
Journal:  J Virol Methods       Date:  1989-01       Impact factor: 2.014

6.  Detection of human parvovirus B19 DNA by using the polymerase chain reaction.

Authors:  W C Koch; S P Adler
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

7.  Antigenic parvovirus B19 coat proteins VP1 and VP2 produced in large quantities in a baculovirus expression system.

Authors:  C S Brown; M M Salimans; M H Noteborn; H T Weiland
Journal:  Virus Res       Date:  1990-03       Impact factor: 3.303

8.  Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19.

Authors:  A L Bruu; S A Nordbø
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

9.  Evaluation of 4 commercial test kits for parvovirus B19-specific IgM.

Authors:  B J Cohen; C M Bates
Journal:  J Virol Methods       Date:  1995-09       Impact factor: 2.014

10.  Recombinant parvovirus B19 capsids as a new substrate for detection of B19-specific IgG and IgM antibodies by an enzyme-linked immunosorbent assay.

Authors:  M M Salimans; M J van Bussel; C S Brown; W J Spaan
Journal:  J Virol Methods       Date:  1992-09       Impact factor: 2.014
View more
  4 in total

1.  Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women.

Authors:  Allyson R Butchko; Jeanne A Jordan
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 2.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 3.  Parvovirus B-19 infection during pregnancy.

Authors:  Anthony Al-Khan; Andrew Caligiuri; Joseph Apuzzio
Journal:  Infect Dis Obstet Gynecol       Date:  2003

4.  Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis.

Authors:  Benedikt Weissbrich; Yvonne Süss-Fröhlich; Hermann J Girschick
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.